Genome-wide association study of treatment response to venlafaxine XR in generalized anxiety disorder

被引：13

作者：

Jung, Jeesun ^{[1
]}

Tawa, Elisabeth A. ^{[2
]}

Muench, Christine ^{[2
]}

Rosen, Allison D. ^{[2
]}

Rickels, Karl ^{[3
]}

Lohoff, Falk W. ^{[2
,3
]}

机构：

[1] NIAAA, Div Intramural Clin & Biol Res, Bethesda, MD 20892 USA

[2] NIAAA, Sect Clin Genom & Expt Therapeut, Bethesda, MD USA

[3] Univ Penn, Dept Psychiat, Mood & Anxiety Disorders Treatment & Res Program, Philadelphia, PA 19104 USA

来源：

PSYCHIATRY RESEARCH | 2017年 / 254卷

关键词：

Pharmacogenetics; Generalized anxiety disorder; Venlafaxine XR; EXTENDED-RELEASE; EXPRESSION; ANTIDEPRESSANTS; MECHANISMS; IMPUTATION; BEHAVIORS;

D O I：

10.1016/j.psychres.2017.04.025

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

We conducted the first genome-wide association study (GWAS) in Generalized Anxiety Disorder (GAD) to identify potential predictors of venlafaxine XR treatment outcome. Ninety-eight European American patients participated in a venlafaxine XR clinical trial for GAD, with Hamilton Anxiety Scale (HAM-A) response/remission at 24 weeks as the primary outcome measure. All participants were genotyped with the Illumina PsychChip, and 266,820 common single nucleotide polymorphisms (SNPs) were analyzed. Although no SNPs reached genome-wide significance, 8 SNPs were marginally associated with treatment response/remission and HAM-A reduction at week 12 and 24 (p < 0.00001). Several identified genes may indicate markers crossing neuropsychiatric diagnostic categories.

引用

页码：8 / 11

页数：4

共 27 条

[1] Antidepressants increase human hippocampal neurogenesis by activating the glucocorticoid receptor [J].

Anacker, C. ;

Zunszain, P. A. ;

Cattaneo, A. ;

Carvalho, L. A. ;

Garabedian, M. J. ;

Thuret, S. ;

Price, J. ;

Pariante, C. M. .

MOLECULAR PSYCHIATRY, 2011, 16 (07) :738-750

[2]

[Anonymous], 2016, MOL PSYCHIAT

[3]

Baldwin David S, 2005, Expert Rev Neurother, V5, P443, DOI 10.1586/14737175.5.4.443

[4] Anxiety disorders and suicidality in the National Comorbidity Survey-Replication [J].

Cougle, Jesse R. ;

Keough, Meghan E. ;

Riccardi, Christina J. ;

Sachs-Ericsson, Natalie .

JOURNAL OF PSYCHIATRIC RESEARCH, 2009, 43 (09) :825-829

[5] Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder - A 6-month randomized controlled trial [J].

Gelenberg, AJ ;

Lydiard, RB ;

Rudolph, RL ;

Aguiar, L ;

Haskins, JT ;

Salinas, E .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (23) :3082-3088

[6] Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epiderniologic Survey on Alcohol and Related Conditions [J].

Grant, BF ;

Hasin, DS ;

Stinson, FS ;

Dawson, DA ;

Ruan, WJ ;

Goldstein, RB ;

Smith, SM ;

Saha, TD ;

Huang, BJ .

PSYCHOLOGICAL MEDICINE, 2005, 35 (12) :1747-1759

[7] SNP imputation in association studies [J].

Halperin, Eran ;

Stephan, Dietrich A. .

NATURE BIOTECHNOLOGY, 2009, 27 (04) :349-351

[8] THE ASSOCIATION BETWEEN ANXIETY DISORDERS AND SUICIDAL BEHAVIORS: A SYSTEMATIC REVIEW AND META-ANALYSIS [J].

Kanwar, Amrit ;

Malik, Shaista ;

Prokop, Larry J. ;

Sim, Leslie A. ;

Feldstein, David ;

Wang, Zhen ;

Murad, M. Hassan .

DEPRESSION AND ANXIETY, 2013, 30 (10) :917-929

[9] Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder [J].

Kato, M. ;

Serretti, A. .

MOLECULAR PSYCHIATRY, 2010, 15 (05) :473-500

[10] SMALL-SAMPLE COMPARISONS OF EXACT LEVELS FOR CHI-SQUARED GOODNESS-OF-FIT STATISTICS [J].

LARNTZ, K .

JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1978, 73 (362) :253-263

← 1 2 3 →